Literature DB >> 3936634

Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.

S G Andrade, J B Magalhães, A L Pontes.   

Abstract

A test was made of the susceptibility of 30 strains of Trypanosoma cruzi to chemotherapy with nifurtimox (Bay 2502) and benznidazole (Ro 7-1051). The strains had previously been classified as type I, II, or III according to their morphobiological and isoenzymic characteristics. Three type I strains, 14 type II strains, and 13 type III strains were studied. Mice were infected with 2 x 10(5) blood forms of these parasites and treated for 90 days with benznidazole or nifurtimox. All the surviving mice were submitted to parasitological tests (direct parasitaemia, xenodiagnosis, inoculation in new-born mice, and haemoculture) and serological tests (indirect immunofluorescence). As the latter remained positive in about 80% of the parasitologically negative animals, the cure rates were based on the more reliable parasitological tests. Type I strains displayed high susceptibility, type II strains showed medium to high susceptibility, and type III strains were highly resistant to both drugs. The fact that a particular strain type, with its own level of susceptibility, usually predominates in a given geographical area may explain the contradictory results after chemotherapy from different endemic areas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936634      PMCID: PMC2536372     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  [Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].

Authors:  S G Andrade; R M Figueira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1977 Sep-Oct       Impact factor: 1.846

2.  [Chagas' disease and blood transfusion].

Authors:  J A Cerisola; A Rabinovich; M Alvarez; C A Di Corleto; J Pruneda
Journal:  Bol Oficina Sanit Panam       Date:  1972-09

3.  Fluorescent antibody test for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test.

Authors:  M E Camargo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1966 Sep-Oct       Impact factor: 1.846

4.  Differences in the susceptibility of Trypanosoma cruzi strains to active chemotherapeutic agents.

Authors:  Z Brener; C A Costa; C Chiari
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1976 Nov-Dec       Impact factor: 1.846

5.  [Clinical therapeutic trial in chronic Chagas' disease using nifurtimox in 3 schedules of long duration].

Authors:  J A Cancado; A A Salgado; U D Marra; J M Alvares; J R Machado
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1975 Mar-Apr       Impact factor: 1.846

6.  Correlation between isoenzyme patterns and biological behaviour of different strains of Trypanosoma cruzi.

Authors:  V Andrade; C Brodskyn; S G Andrade
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

7.  [Experimental study on the resistance of a strain of Trypanosoma cruzi to Bay 2502].

Authors:  S G Andrade; Z A Andrade; R M Figueira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1977 Mar-Apr       Impact factor: 1.846

8.  [Etiological treatment of Chagas' disease].

Authors:  A Rassi
Journal:  Arq Bras Cardiol       Date:  1982-04       Impact factor: 2.000

9.  Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.

Authors:  A U Krettli; Z Brener
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

  9 in total
  29 in total

1.  Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase.

Authors:  F S Buckner; A J Wilson; W C Van Voorhis
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

2.  Croton cajucara crude extract and isolated terpenes: activity on Trypanosoma cruzi.

Authors:  Monica C O Campos; Kelly Salomão; Denise B Castro-Pinto; Leonor L Leon; Helene S Barbosa; Maria Aparecida M Maciel; Solange L de Castro
Journal:  Parasitol Res       Date:  2010-08-03       Impact factor: 2.289

3.  Efficacy and mechanisms of alpha-solasonine-and alpha-solamargine-induced cytolysis on two strains of Trypanosoma cruzi.

Authors:  Christopher A Hall; Traci Hobby; Martin Cipollini
Journal:  J Chem Ecol       Date:  2006-11       Impact factor: 2.626

4.  Treatment of chronic experimental Trypanosoma cruzi infections in mice with MK-436, a 2-substituted 5-nitroimidazole.

Authors:  S G Andrade; R C Silva; C M Santiago
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

5.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

6.  In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

Authors:  Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Beatriz Philot Pavão; Julianna Siciliano Araújo; Claudia Alessandra Fortes Aiub; Patrícia Bernardino da Silva; Jessica Lionel; Constança Britto; Kwangho Kim; Gary Sulikowski; Tatiana Y Hargrove; Michael R Waterman; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

7.  Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes.

Authors:  Max Jean de Ornelas Toledo; Maria Terezinha Bahia; Cláudia M Carneiro; Olindo Assis Martins-Filho; Michel Tibayrenc; Christian Barnabé; Washington Luis Tafuri; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice.

Authors:  S G Andrade; L A Freitas; S Peyrol; A R Pimentel; M Sadigursky
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

9.  Genotyping of Trypanosoma cruzi sublineage in human samples from a North-East Argentina area by hybridization with DNA probes and specific polymerase chain reaction (PCR).

Authors:  Cristina Diez; Virginia Lorenz; Silvia Ortiz; Verónica Gonzalez; Andrea Racca; Iván Bontempi; Silvia Manattini; Aldo Solari; Iván Marcipar
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

10.  A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease.

Authors:  Juan M Bustamante; Fernando Sanchez-Valdez; Angel M Padilla; Brooke White; Wei Wang; Rick L Tarleton
Journal:  Sci Transl Med       Date:  2020-10-28       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.